Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Hayden

Showing results (41-50 of 391) with videos related to

Pageof 40
Sort By:
The Journal of Infectious Diseases|December 4, 2012
The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemicFred Y Aoki, Frederick G Hayden
Clinics in Laboratory Medicine|December 1, 1987
Antiviral chemotherapy and prophylaxis of viral respiratory diseaseS J Sperber, F G Hayden
Antiviral Research|December 1, 1989
Protective effect of rhinovirus receptor blocking antibody in human fibroblast cellsS J Sperber, F G Hayden
The Journal of Infectious Diseases|February 1, 2012
Fatal influenza B infections: time to reexamine influenza research prioritiesJonathan A McCullers, Frederick G Hayden
Archives of Family Medicine|October 14, 2000
Picornavirus infections: a primer for the practitionerH A Rotbart, F G Hayden
Clinical Pharmacokinetics|August 3, 1999
Zanamivir. A potent and selective inhibitor of influenza A and B virusesF Y Aoki, F G Hayden
The Journal of Infectious Diseases|September 1, 1983
Intranasal interferon alpha 2 for prevention of rhinovirus infection and illnessF G Hayden, J M Gwaltney
The Journal of Infectious Diseases|August 1, 1984
Intranasal interferon-alpha 2 treatment of experimental rhinoviral coldsF G Hayden, J M Gwaltney
Annals of Internal Medicine|September 21, 2005
Influenza A (H5N1): will it be the next pandemic influenza? Are we ready?John G Bartlett, Frederick G Hayden
Drugs|November 7, 1998
New approaches to influenza chemotherapy. Neuraminidase inhibitorsD P Calfee, F G Hayden
Pageof 40

Showing results (41-50 of 391) with videos related to

Sort By:
Pageof 40
The Journal of Infectious Diseases|December 4, 2012
The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemicFred Y Aoki, Frederick G Hayden
Clinics in Laboratory Medicine|December 1, 1987
Antiviral chemotherapy and prophylaxis of viral respiratory diseaseS J Sperber, F G Hayden
Antiviral Research|December 1, 1989
Protective effect of rhinovirus receptor blocking antibody in human fibroblast cellsS J Sperber, F G Hayden
The Journal of Infectious Diseases|February 1, 2012
Fatal influenza B infections: time to reexamine influenza research prioritiesJonathan A McCullers, Frederick G Hayden
Archives of Family Medicine|October 14, 2000
Picornavirus infections: a primer for the practitionerH A Rotbart, F G Hayden
Clinical Pharmacokinetics|August 3, 1999
Zanamivir. A potent and selective inhibitor of influenza A and B virusesF Y Aoki, F G Hayden
The Journal of Infectious Diseases|September 1, 1983
Intranasal interferon alpha 2 for prevention of rhinovirus infection and illnessF G Hayden, J M Gwaltney
The Journal of Infectious Diseases|August 1, 1984
Intranasal interferon-alpha 2 treatment of experimental rhinoviral coldsF G Hayden, J M Gwaltney
Annals of Internal Medicine|September 21, 2005
Influenza A (H5N1): will it be the next pandemic influenza? Are we ready?John G Bartlett, Frederick G Hayden
Drugs|November 7, 1998
New approaches to influenza chemotherapy. Neuraminidase inhibitorsD P Calfee, F G Hayden
Pageof 40